Gemphire shares soar on lead drug's potential

2 July 2018

Shares in cardiometabolic disorders specialist Gemphire Therapeutics (Nasdaq: GEMP) nearly doubled in value on Friday following encouraging results from a Phase IIb trial of gemcabene.

The trial met the primary endpoint of significantly reducing triglycerides (TGs) in severe hypertriglyceridemia (SHTG) patients, and, as well as meeting the study’s secondary endpoints of lowering other biomarkers that are typically elevated in a broad range of dyslipidemic conditions, gemcabene also showed evidence of safety and tolerability in combination with statins.

Steven Gullans, the US company’s chief executive, said: “We are pleased to reach this milestone of meeting both primary and multiple secondary endpoints and look forward to advancing gemcabene into Phase III trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK